RecruitingPhase 3NCT07498426

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

A Phase III, Randomized, Placebo-controlled, Parallel Group, Double-blind Study to Evaluate the Efficacy and Safety of NIO752 in Participants With Progressive Supranuclear Palsy Followed by an Open Label Extension

Sponsor

Novartis Pharmaceuticals

Enrollment

300 participants

Start Date

Jun 3, 2026

Study Type

INTERVENTIONAL

Conditions

Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Summary

This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.

Eligibility

Min Age: 41 YearsMax Age: 81 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying NIO752 and a drug called Placebo for people with progressive supranuclear palsy richardson syndrome (psp-rs). The study is currently recruiting participants at 6 locations. People eligible for this study include aged 41 Years to 81 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNIO752

Solution of antisense oligonucleotide.

DRUGPlacebo

Placebo solution

Locations(24)

Univ of California San Francisco

San Francisco, California, United States

CenExcel Rocky Mtn Clin Research

Englewood, Colorado, United States

Mayo Jacksonville

Jacksonville, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

Novartis Investigative Site

Melbourne, Victoria, Australia

Novartis Investigative Site

Caen, France

Novartis Investigative Site

Créteil, France

Novartis Investigative Site

Paris, France

Novartis Investigative Site

Toulouse, France

Novartis Investigative Site

Bonn, North Rhine-Westphalia, Germany

Novartis Investigative Site

Düsseldorf, North Rhine-Westphalia, Germany

Novartis Investigative Site

Leipzig, Saxony, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Stadtroda, Germany

Klinik für Neurologie (Schwerpunkt Neurodegeneration)

Ulm, Germany

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Roma, RM, Italy

Novartis Investigative Site

Kodaira, Tokyo, Japan

Novartis Investigative Site

Rotterdam, South Holland, Netherlands

Novartis Investigative Site

Barcelona, Spain

Novartis Investigative Site

Las Palmas GC, Spain

Novartis Investigative Site

Madrid, Spain

Novartis Investigative Site

Madrid, Spain

Novartis Investigative Site

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07498426